• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ByHeart Appoints Amy Schulman as Chair of the Board of Directors, Further Solidifying its Position as a Leader in the Infant Nutrition Category

    3/5/24 9:06:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALNY alert in real time by email

    As former leader of Pfizer's infant nutrition and consumer healthcare businesses, Schulman brings extensive experience in the space, in addition to serving on the boards of several biotech and pharmaceutical companies; This marks ByHeart's first non-executive Board chair appointment

    In addition to Schulman, ByHeart appoints Niall Mullane, PhD, as Chief Quality Officer to join the experienced executive team; Mullane brings 15 years of quality and food safety experience in the infant nutrition category

    NEW YORK, March 5, 2024 /PRNewswire/ --Today, ByHeart, the next-generation baby nutrition company, announced the appointment of Amy Schulman, managing partner at Polaris partners, as Chair of the Board. A stalwart supporter of ByHeart since its inception, Schulman's designation signifies a pivotal moment for the company as it experiences momentous growth and solidifies its position as an industry leader.

    ByHeart Logo (PRNewsfoto/ByHeart)

    Schulman's support of ByHeart dates back to the early stages of the company's development, when she played a crucial role as one of the first institutional investors, with Polaris co-leading the series A funding round and participating in each additional round since. With a distinguished career that spans various roles at Pfizer, including President of Pfizer Nutrition and Pfizer Consumer Healthcare, Schulman brings a wealth of experience and expertise in infant formula and consumer health.

    "Amy's insights and passion for health innovation and social impact align with ByHeart's mission," said ByHeart Co-Founder and CEO Ron Belldegrun. "We chose Amy as the Chair because of her extensive track record in life sciences and infant nutrition. No one better understands what it takes to apply 21st century functional nutrition to revolutionize babies' first food and set a strong foundation for future health."

    In addition to her new role at ByHeart, Schulman also serves as Chair of the Board of Directors of Alnylam Pharmaceuticals (NASDAQ:ALNY) and as executive chair of Lyndra Therapeutics, where she was co-founder and the company's initial CEO. She is also a managing partner at Polaris Partners and Co-Founder of the Polaris Innovation Fund, serving on the firm's life sciences investment team and a senior lecturer at Harvard Business School. Her commitment to health also extends to her board appointments on the Boards of Action Against Hunger, Mount Sinai Hospital (where she co-chairs the Innovations Committee), and the California Institute of Technology. She is a member of Singapore's Health and Biomedical Sciences International Advisory Council and the LifeSci NYC Advisory Council.

    "I have been a staunch supporter of ByHeart from its early days, and I am honored to now chair their board," said Schulman. "The company takes a rare but much needed innovative, evidence-based approach to infant nutrition. This approach together with their unwavering commitment to quality and safety and dedication to making formula parents and babies love is setting a new standard. I look forward to working with the ByHeart team and the amazing founders on their journey to enhance the wellbeing of generations to come."

    "We're honored that Amy agreed to chair our board. She leads with integrity and a people-first commitment, while also always thoughtfully challenging the status quo and seeking ways to push the bounds of what's possible to drive health innovation," said Mia Funt, ByHeart Co-founder and President. "Also, on a personal note, she's an inspiring business woman and family woman, who welcomes open conversations about the daily choices we make between family and career. We need more female leaders like her to set an example for the next generation."

    ByHeart continues to build an impressive roster of talent with the addition of Niall Mullane, PhD, as Chief Quality Officer, joining the experienced executive team consisting of: Georg Krause-Vilmar, Chief Legal Officer; Bob Peruzzi, Chief Financial Officer; Elias Aoukar, Chief Operating Officer; Devon Kuehn, MD, Chief Medical Officer; Ron Belldegrun, CEO and Co-Founder; and Mia Funt, President and Co-Founder. Mullane is a global quality leader with over 15 years of experience working in the infant formula industry and brings unparalleled value to ByHeart's quality control and safety practices. He previously held senior quality and food safety positions with the industry's major players, Mead Johnson and Reckitt, in both their global and regional operational quality teams. With an extensive background in food safety oversight and as a microbiologist with a unique PhD specifically in Cronobacter, Mullane will play an integral role in managing the continued success of ByHeart's domestic supply chain and infrastructure. Alongside his distinctive industry experience, Mullane is fervently committed to upholding ByHeart – and the broader industry – to the highest global standards of quality for infant formula, the fundamental nutrition for babies worldwide.

    This announcement comes at a significant juncture for ByHeart, following the successful integration of two new manufacturing facilities, which solidified the company's ownership of its end-to-end manufacturing supply chain in the United States. ByHeart now boasts a full omnichannel presence with direct-to-consumer and retail offerings at Target both in-store and online, further positioning itself as a dynamic force within the infant formula market. ByHeart remains dedicated to advancing infant nutrition through science, innovation and a commitment to excellence.

    About ByHeart

    Founded in 2016 and based in New York City with manufacturing facilities in Pennsylvania, Oregon and Iowa, ByHeart is the baby nutrition company dedicated to empowering parents with choices for a better feeding future. ByHeart is only one of five fully integrated, FDA-registered infant formula brands in the country, and ByHeart facilities are driven by nutritional excellence and a farm-to-formula verified™ quality program. For more information on ByHeart, visit https://byheart.com/.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/byheart-appoints-amy-schulman-as-chair-of-the-board-of-directors-further-solidifying-its-position-as-a-leader-in-the-infant-nutrition-category-302080011.html

    SOURCE ByHeart

    Get the next $ALNY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALNY

    DatePrice TargetRatingAnalyst
    3/31/2025$353.00Buy
    Redburn Atlantic
    3/24/2025$280.00 → $328.00Neutral → Overweight
    Analyst
    11/12/2024Peer Perform → Underperform
    Wolfe Research
    10/16/2024Sector Outperform
    Scotiabank
    8/16/2024$198.00 → $370.00Neutral → Buy
    Goldman
    2/16/2024$173.00Buy → Neutral
    Goldman
    2/15/2024Peer Perform
    Wolfe Research
    12/8/2023$171.00Equal Weight
    Wells Fargo
    More analyst ratings

    $ALNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

      SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

      11/12/24 9:50:12 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

      SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

      11/8/24 10:34:33 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

      SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

      8/12/24 9:40:06 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNY
    Leadership Updates

    Live Leadership Updates

    See more
    • Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

      Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company's Board of Directors, effective as of May 8, 2025. Dr. Sharp has served as a key advisor to Alnylam since he co-founded the Company in 2002. Dr. Sharp will remain a member of the Alnylam Scientific Advisory Board. "Phil helped pioneer the RNAi revolution, sparking the scientific collaboration that led to Alnylam's founding and the development of a transformative new class of medicines," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "He has provided invaluable guidance over the past twenty-two years that has

      3/5/25 7:00:00 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ByHeart Appoints Amy Schulman as Chair of the Board of Directors, Further Solidifying its Position as a Leader in the Infant Nutrition Category

      As former leader of Pfizer's infant nutrition and consumer healthcare businesses, Schulman brings extensive experience in the space, in addition to serving on the boards of several biotech and pharmaceutical companies; This marks ByHeart's first non-executive Board chair appointment In addition to Schulman, ByHeart appoints Niall Mullane, PhD, as Chief Quality Officer to join the experienced executive team; Mullane brings 15 years of quality and food safety experience in the infant nutrition category NEW YORK, March 5, 2024 /PRNewswire/ --Today, ByHeart, the next-generation baby nutrition company, announced the appointment of Amy Schulman, managing partner at Polaris partners, as Chair of th

      3/5/24 9:06:00 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alnylam Announces Appointment of Peter Kellogg to Board of Directors

      – Experienced Business and Financial Leader, Kellogg Served as Chief Financial Officer at Biogen, Merck, and Celgene – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors. Mr. Kellogg is an accomplished industry executive with extensive global financial and strategic management experience. "Mr. Kellogg joins our Board at a pivotal moment for Alnylam as we continue on the path to achieving our P5x25 strategy and fulfilling our ambition to become a top-tier biopharmaceutical company," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "His financial expertise and experi

      3/8/23 7:00:00 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNY
    SEC Filings

    See more
    • SEC Form 10-Q filed by Alnylam Pharmaceuticals Inc.

      10-Q - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

      5/1/25 8:15:07 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alnylam Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

      5/1/25 8:09:08 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Alnylam Pharmaceuticals Inc.

      SCHEDULE 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

      4/7/25 11:51:33 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNY
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ALNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ALNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference

      Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025 at 11:20 am PT (2:20 pm ET). A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event. About Alnylam Pharmaceuticals Alnylam (NASDAQ:ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and

      5/5/25 10:00:00 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

      − Achieved First Quarter 2025 Global Net Product Revenues of $469 Million, Representing 28% Year-Over-Year Growth Compared to Q1 2024 Driven by Continued Strong Growth of 36% from hATTR-PN Franchise – − Received U.S. Food and Drug Administration (FDA) Approval of AMVUTTRA® (vutrisiran) to Reduce Cardiovascular Death, Cardiovascular Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) – − AMVUTTRA ATTR-CM Launch Underway with Strong Progress Across All Early Commercial Indicators – − Approval of Qfitlia™ Represents the First and Only Therapeutic to Treat Hemophilia A or B With or Without Inhibitors and the Sixth Alnylam-Discovered

      5/1/25 8:00:00 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

      − Recommended Approval Based on the Pivotal HELIOS-B Phase 3 Study in which Vutrisiran Demonstrated Significant Reductions in Mortality and Cardiovascular Events, While Preserving Functional Status and Quality of Life – − Offers a Clinically Differentiated Approach with Rapid and Sustained Transthyretin (TTR) Knockdown and Quarterly Subcutaneous Dosing – − Follows Recent Approvals in the U.S. and Brazil − − European Commission Decision Expected in June 2025 – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopte

      4/28/25 8:00:00 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Redburn Atlantic initiated coverage on Alnylam Pharma with a new price target

      Redburn Atlantic initiated coverage of Alnylam Pharma with a rating of Buy and set a new price target of $353.00

      3/31/25 8:12:33 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alnylam Pharma upgraded by Analyst with a new price target

      Analyst upgraded Alnylam Pharma from Neutral to Overweight and set a new price target of $328.00 from $280.00 previously

      3/24/25 8:23:59 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alnylam Pharma downgraded by Wolfe Research

      Wolfe Research downgraded Alnylam Pharma from Peer Perform to Underperform

      11/12/24 7:27:31 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Greenstreet Yvonne gifted 41,311 shares, decreasing direct ownership by 42% to 57,324 units (SEC Form 4)

      4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

      5/6/25 5:05:38 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CMO & EVP Dev & Med Affairs Garg Pushkal sold $2,864,985 worth of shares (9,766 units at $293.36) and exercised 5,445 shares at a strike of $42.22, decreasing direct ownership by 18% to 20,221 units (SEC Form 4)

      4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

      3/25/25 4:10:23 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Pyott David E I exercised 7,440 shares at a strike of $88.95 and sold $2,224,560 worth of shares (7,440 units at $299.00) (SEC Form 4)

      4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

      3/25/25 4:09:47 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for GIVLAARI issued to ALNYLAM PHARMS INC

      Submission status for ALNYLAM PHARMS INC's drug GIVLAARI (SUPPL-7) with active ingredient GIVOSIRAN SODIUM has changed to 'Approval' on 04/29/2024. Application Category: NDA, Application Number: 212194, Application Classification: Labeling

      4/30/24 1:44:03 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for OXLUMO issued to ALNYLAM PHARMS INC

      Submission status for ALNYLAM PHARMS INC's drug OXLUMO (SUPPL-4) with active ingredient LUMASIRAN SODIUM has changed to 'Approval' on 09/19/2023. Application Category: NDA, Application Number: 214103, Application Classification: Labeling

      9/20/23 2:36:38 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for AMVUTTRA issued to ALNYLAM PHARMS INC

      Submission status for ALNYLAM PHARMS INC's drug AMVUTTRA (SUPPL-2) with active ingredient VUTRISIRAN has changed to 'Approval' on 02/16/2023. Application Category: NDA, Application Number: 215515, Application Classification: Labeling

      2/17/23 12:30:09 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNY
    Financials

    Live finance-specific insights

    See more
    • Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

      − Achieved First Quarter 2025 Global Net Product Revenues of $469 Million, Representing 28% Year-Over-Year Growth Compared to Q1 2024 Driven by Continued Strong Growth of 36% from hATTR-PN Franchise – − Received U.S. Food and Drug Administration (FDA) Approval of AMVUTTRA® (vutrisiran) to Reduce Cardiovascular Death, Cardiovascular Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) – − AMVUTTRA ATTR-CM Launch Underway with Strong Progress Across All Early Commercial Indicators – − Approval of Qfitlia™ Represents the First and Only Therapeutic to Treat Hemophilia A or B With or Without Inhibitors and the Sixth Alnylam-Discovered

      5/1/25 8:00:00 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results

      Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday, May 1, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2025 results as well as expectations for the future via conference call on Thursday, May 1, 2025 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event. About Alnylam Pharmaceuticals A

      4/17/25 8:00:00 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

      − Novel Mechanism of Action Delivers Rapid Knockdown of Transthyretin, Addressing the Disease at its Source – − Proven Consistency of Effect on Cardiovascular Outcomes, Function, and Quality of Life in ATTR-CM Population Representative of Today's Patients – – Only Therapeutic Approved in the U.S. to Address Both Cardiomyopathy and Polyneuropathy Manifestations of ATTR Amyloidosis − – Alnylam Offers Multiple Programs to Support Broad and Seamless Patient Access; Majority of Patients Expected to Pay $0 in Out-of-Pocket Costs for AMVUTTRA – – Alnylam to Host Conference Call Today at 6:00 pm ET – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today anno

      3/20/25 5:54:00 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care